Literature DB >> 24821178

Spectrum of biopsy-proven kidney disease in children at a Jordanian Hospital.

Reem Hadidi1, May Hadidi, Ma'en alDabbas.   

Abstract

To determine the patterns of renal disease among Jordanian children based on kidney biopsy results as well as correlating clinical presentation with histopathological diagnosis, we studied the medical records of 55 children who had kidney-biopsy kidney disease at the Prince Hamza Hospital from August 2006 to April 2012. The most common indication for biopsies was steroid-resistant nephrotic syndrome (25%), followed by steroid-dependent nephrotic syndrome (20%). The most common diagnosis of primary glomerular disease was minimal change disease (27%), followed by focal segmental glomerulosclerosis (21%), mesangioproliferative glomerulonephritis (12.7%) and IgA nephropathy (7.3%). The most common secondary renal disease was Henoch-Schonlein purpura (HSP) in 10.9% of the patients, followed by systemic lupus erythematosus in 9.1%. The kidney biopsy was normal in 3.6%. Cyclosporine protocol biopsy was performed in four (7.3%) patients. Gross hematuria after kidney biopsy occurred in 5.5% of cases; however, none of these patients required blood transfusion. Kidney biopsy is a safe procedure that needs to be performed once indicated and our results are comparable with those carried out elsewhere in Jordan. The study also shows the importance of establishing a national registry for pediatric renal disease.

Entities:  

Mesh:

Year:  2014        PMID: 24821178     DOI: 10.4103/1319-2442.132238

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  6 in total

1.  Risk factors for complications of percutaneous ultrasound-guided renal biopsy in children.

Authors:  Jhao-Jhuang Ding; Shih-Hua Lin; Jing-Long Huang; Tai-Wei Wu; Shao-Hsuan Hsia; Jainn-Jim Lin; Yu-Ching Chou; Min-Hua Tseng
Journal:  Pediatr Nephrol       Date:  2019-11-14       Impact factor: 3.714

2.  The Spectrum of Biopsy-Proven Glomerular Diseases among Children in China: A National, Cross-Sectional Survey.

Authors:  Sheng Nie; Wenjuan He; Ting Huang; Diankun Liu; Guobao Wang; Jian Geng; Nan Chen; Gang Xu; Ping Zhang; Yang Luo; Jing Nie; Xin Xu; Fan Fan Hou
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

3.  Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up.

Authors:  Ann Christin Gjerstad; Rannveig Skrunes; Camilla Tøndel; Anders Åsberg; Sabine Leh; Claus Klingenberg; Henrik Døllner; Clara Hammarstrøm; Anna Kristina Bjerre
Journal:  Pediatr Nephrol       Date:  2022-08-22       Impact factor: 3.651

4.  Kidney disease profile and encountered problems during follow-up in Syrian refugee children: a multicenter retrospective study.

Authors:  Ayse Balat; Beltinge Demircioglu Kilic; Bagdagul Aksu; Mehtap Akbalik Kara; Mithat Buyukcelik; Ayse Agbas; Fehime Kara Eroglu; Tulin Gungor; Demet Alaygut; Nurdan Yildiz; Funda Bastug; Bahriye Atmis; Engin Melek; Midhat Elmaci; Sebahat Tulpar; Cemile Pehlivanoglu; Serra Surmeli Doven; Elif Comak; Yilmaz Tabel; Atilla Gemici; Berfin Uysal; Gamze Seval Ozzorlar; Nuran Kuçuk; Ali Delibas; Gul Ozcelik; Nilufer Goknar; Ismail Dursun; Pelin Ertan; Ipek Akil Ozunan; Ferah Sonmez
Journal:  Pediatr Nephrol       Date:  2021-07-31       Impact factor: 3.714

5.  Characterization and Etiopathogenic Approach of Pediatric Renal Biopsy Patients in a Colombian Medical Center from 2007-2017.

Authors:  Mayerly Prada Rico; Carmen Inés Rodríguez Cuellar; Monica Fernandez Hernandez; Luz Stella González Chaparro; Olga Lucía Prado Agredo; Ricardo Gastelbondo Amaya
Journal:  Int J Nephrol       Date:  2018-06-28

6.  Renal histopathology spectrum in children with kidney diseases in Saudi Arabia, 1998-2017.

Authors:  Khalid Alhasan; Noura M Aloudah; Amaar A Bakhit; Yassin M Alhamad; Kechrid M Chihabeddine; Talal A Alfaadhel; Tariq E Aljohani; Hanadi M Alhozali; Abdulkareem O Alsuwaida
Journal:  Saudi Med J       Date:  2020-04       Impact factor: 1.484

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.